Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.57 |
| ▸ | GHSR | Q92847 | 3/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.47 |
| ▸ | ITGAL | P20701 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30911281 | 1.00 | SLC15A2 (0.74) | SLC15A2CYP3A4SLC7A5CPB2GHSR | |
| SCHEMBL29014876 | 0.91 | SLC15A2 (0.63) | SLC15A2CYP3A4SLC7A5CPB2GHSR | |
| SCHEMBL29774683 | 0.91 | SLC15A2 (0.72) | SLC15A2CYP3A4SLC7A5CPB2GHSR | |
| SCHEMBL29774690 | 0.91 | SLC15A2 (0.72) | SLC15A2CYP3A4SLC7A5CPB2GHSR | |
| SCHEMBL28027302 | 0.91 | SLC15A2 (0.71) | SLC15A2CYP3A4SLC7A5CPB2GHSR | |
| SCHEMBL30409074 | 0.91 | SLC15A2 (0.71) | SLC15A2CYP3A4SLC7A5CPB2GHSR | |
| SCHEMBL27687339 | 0.88 | SLC15A2 (0.63) | SLC15A2CYP3A4SLC7A5CPB2GHSR | |
| SCHEMBL22217022 | 0.87 | SLC15A2 (0.79) | SLC15A2CYP3A4SLC7A5CPB2GHSR | |
| SCHEMBL21828671 | 0.86 | CYP3A4 (0.68) | SLC15A2CYP3A4SLC7A5ITGB2ICAM1 | |
| SCHEMBL27806351 | 0.86 | CYP3A4 (0.60) | SLC15A2CYP3A4SLC7A5CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121086010-A | STPEN novel polypeptide and application thereof in cardiovascular improvement medicines | 浙江国本医药集团有限公司 | 2025-12-09 | — | — | CN | disclosed |
| CN-116585283-B | Lansoprazole enteric capsule and preparation method thereof | 桂林华信制药有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-116807990-B | Esomeprazole magnesium enteric capsule and preparation method thereof | 桂林华信制药有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118146305-A | Licorice oligopeptide-a, extraction method and application thereof | 河南省儿童医院郑州儿童医院 | 2024-06-07 | — | — | CN | disclosed |
| CN-114380695-B | Novel method for simply and rapidly realizing C-C bond formation reaction | 吉林大学 | 2024-02-13 | — | — | CN | disclosed |
| CN-117486974-A | Seafood mushroom sour peptide and extraction method and application thereof | 陕西科技大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-116807990-A | Esomeprazole magnesium enteric capsule and preparation method thereof | 桂林华信制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230303626-A1 | MACROCYCLIC POLYPEPTIDES | UNIVERSITY OF WASHINGTON | 2023-09-28 | — | — | US | disclosed |
| CN-116585283-A | Lansoprazole enteric capsule and preparation method thereof | 桂林华信制药有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-111770778-B | Extract of Pelargonium gracilis rich in organic acid, cosmetic composition containing the same and cosmetic use thereof | ISP投资有限责任公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116396876-A | Saccharomyces cerevisiae engineering bacteria for producing ginsenoside Rd and construction method thereof | 云南农业大学 | 2023-07-07 | — | — | CN | disclosed |
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | EAGLE RESOLUTE INVESTMENT LLC | 2023-06-08 | — | — | US | disclosed |
| US-11524979-B2 | Macrocyclic polypeptides | UNIVERSITY OF WASHINGTON (US) | 2022-12-13 | — | — | US | disclosed |
| CN-101384274-B | Compositions comprising peptides having non-naturally occurring amino acids and methods of use thereof | AVON PROD INC | 2012-08-22 | — | — | CN | disclosed |
| CN-101128126-B | Gelation of anionic polysaccarides using protein hydrolysates | UNILEVER NEDERLAND B.V. (NL) | 2011-11-30 | — | — | CN | disclosed |
| CN-101384274-A | Compositions comprising peptides having non-naturally occurring amino acids and methods of use thereof | AVON PROD INC (US) | 2009-03-11 | — | — | CN | disclosed |
| CN-101128126-A | Gelation of anionic polysaccarides using protein hydrolysates | CSM NEDERLAND BV (NL) | 2008-02-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | VIP, DNPEP, CD74 | SLC15A2 1447/4885CYP3A4 2675/4885SLC7A5 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.